000007616 001__ 7616
000007616 005__ 20240124114247.0
000007616 0247_ $$2DOI$$a10.6083/m4bc3z3s
000007616 037__ $$aETD
000007616 245__ $$aDiscovering new vaccines and therapeutics to treat chikungunya virus infections: characterization of an antiviral, a therapy, and a vaccine
000007616 260__ $$bOregon Health and Science University
000007616 269__ $$a2017
000007616 336__ $$aDissertation
000007616 502__ $$bPh.D.
000007616 520__ $$aChikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes acute febrile illness and long-lasting joint and muscle pain. The 2013-2016 CHIKV outbreaks in the Americas is one example of how CHIKV can rapidly spread through areas of CHIKV seronegative individuals and cause widespread severe and debilitating arthritic disease. Since there is no currently available licensed vaccine or antiviral for preventing or treating CHIKV and other alphaviruses, there is urgent need to understand the basic processes of viral replication and viral immunity to develop effective prophylactic and therapeutic treatments. In my dissertation, I describe three different strategies to uncover new aspects of CHIKV biology by testing a small molecule inhibitor, a monoclonal antibody therapy, and a novel T cell vaccine.
000007616 542__ $$fIn copyright - single owner
000007616 650__ $$aAlphavirus$$014493
000007616 650__ $$aChikungunya virus$$016460
000007616 6531_ $$avaccines antibodies
000007616 6531_ $$aviral
000007616 691__ $$aSchool of Medicine$$041369
000007616 692__ $$aDepartment of Molecular Microbiology and Immunology$$041429
000007616 7001_ $$aBroeckel, Rebecca
000007616 8564_ $$91dd73328-5c0d-4c53-8b4c-733160652f28$$s14458850$$uhttps://digitalcollections.ohsu.edu/record/7616/files/Broeckel.Rebecca.2017.pdf
000007616 905__ $$a/rest/prod/2n/49/t2/19/2n49t2199
000007616 909CO $$ooai:digitalcollections.ohsu.edu:7616$$pstudent-work
000007616 980__ $$aTheses and Dissertations